Inhibition by dehydroepiandrosterone of butylated hydroxyanisole (BHA) promotion of rat-bladder carcinogenesis and enhancement of BHA-induced forestomach hyperplasia.
The effects of dehydroepiandrosterone (DHEA) with/without ribonucleoside (RNs) supplementation on butylated hydroxyanisole (BHA) bladder-tumor promotion and forestomach carcinogenesis were investigated. Male F344 rats were given N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in their drinking water for 4 weeks and then received basal diet or diet containing BHA, DHEA, a mixture of RNs, BHA + DHEA or BHA + DHEA + RNs for 32 weeks. The occurrences of papillomas and carcinomas in the urinary bladder were increased in the groups given BHA or BHA + DHEA + RNs, as compared with control group values. In comparison with the BHA group, the BHA + DHEA group incidences and numbers of these tumors were decreased. However, the incidence and multiplicity of papillomas in the group given BHA + DHEA + RNs were again elevated. DNA synthesis levels in normal-appearing bladder epithelium, but not tumor cells, were closely correlated with the observed level of promotion in most groups. The case of DHEA alone proved exceptional in that DNA synthesis was markedly decreased without any significant influence on lesion development. In the forestomach, DHEA, which itself was associated with slight although non-significant hyperplasia, enhanced BHA-induced epithelial lesions, characterized by marked basal-cell proliferation and keratin-cyst formation, independently of additional RNs administration. Our results suggest that the anti-promoting effects of DHEA in the bladder depend on a deficiency in the pentose phosphates necessary for production of nucleosides. Organ-specific modulation is indicated by the enhancing effects of DHEA on BHA-induced forestomach hyperplasia.
Shibata
M A
MA
First Department of Pathology, Nagoya City University Medical School, Japan.
Shirai
T
T
Asakawa
E
E
Hirose
M
M
Fukushima
S
S
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002083:Butylated Hydroxyanisole; D004247:DNA / Q000187:drug effects; D003687:Dehydroepiandrosterone / Q000494:pharmacology*; D004357:Drug Synergism; D006965:Hyperplasia / Q000139:chemically induced; D008297:Male; D011230:Precancerous Conditions / Q000139:chemically induced* / Q000517:prevention & control; D051381:Rats; D011916:Rats, Inbred F344; D013270:Stomach / Q000187:drug effects / Q000473:pathology*; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced* / Q000517:prevention & control; D014554:Urination / Q000187:drug effects
D002083:Butylated Hydroxyanisole; D003687:Dehydroepiandrosterone; D004247:DNA